Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1580 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
1 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
2 Recruiting Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
Intervention:
3 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
4 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
5 Unknown  Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Condition: Lymphedema
Intervention: Drug: near-infrared fluorescence imaging
6 Recruiting E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox (E7777)
7 Recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Non-hodgkin Lymphoma or Multiple Myeloma
Conditions: Non-Hodgkin Lymphoma;   Multiple Myeloma
Intervention: Drug: ABT-199
8 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
9 Recruiting A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
10 Unknown  TREatment of degeNerative and Neoplastic Diseases With Rituximab
Condition: Diffuse Large B Cell Lymphoma
Intervention: Biological: Rituximab
11 Recruiting Bronchoscopic Sampling Techniques in Sarcoidosis
Conditions: Mediastinal Lymph Node Enlargement;   Sarcoidosis;   Tuberculosis;   Lymphomas
Interventions: Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB);   Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA);   Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes;   Procedure: Bronchoalveolar lavage (BAL);   Procedure: Endobronchial forceps biopsy
12 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
Intervention:
13 Recruiting Rituximab&Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL
Conditions: Primary Central Nervous System Lymphoma;   Brain and Central Nervous System Tumors;   Lymphoma
Interventions: Drug: Rituxan;   Drug: Carboplatin;   Drug: Methotrexate;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Leucovorin
14 Recruiting Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Conditions: Bacterial Infection;   Malignant Neoplasm;   Methicillin-resistant Staphylococcus Aureus Infection;   Nonmalignant Neoplasm;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: chlorhexidine gluconate;   Procedure: wound care management;   Other: questionnaire administration;   Other: laboratory biomarker analysis
15 Recruiting Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Conditions: Lymphoma;   Chronic Lymphocytic Leukemia;   Non-Hodgkin Lymphoma;   T-cell Lymphoma
Interventions: Drug: IPI-145;   Drug: Rituximab;   Drug: Bendamustine
16 Recruiting Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: GDPT regimen;   Drug: CHOP regimen
17 Unknown  Chronic Graft-Versus-Host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-Identical Siblings in Patients With Acute Leukemia
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin)
18 Not yet recruiting A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Condition: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Interventions: Drug: Imprime PGG;   Drug: Rituximab
19 Unknown  Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL
Interventions: Drug: Revlimid, rituximab;   Drug: Relapsed or refractory CLL. Lenalidomide and Rituximab
20 Recruiting Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Conditions: Multiple Myeloma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Romidepsin;   Drug: Lenalidomide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years